Compare Mesoblast Limited (MESO) vs iShares TIPS Bond ETF (TIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs iShares TIPS Bond ETF — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.75B), while iShares TIPS Bond ETF trades at $104.41 (market cap $14.17B). The key difference: iShares TIPS Bond ETF is far larger — about 8.1× Mesoblast Limited's market cap, and Mesoblast Limited is more actively traded (239,027 versus 1,780,688). Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and iShares TIPS Bond ETF for 61 Days on average.
| MESO | TIP | |
|---|---|---|
Market Cap | $1.75B | $14.17B |
Volume | 239,027 | 1,780,688 |
Sector | Health | Fixed Income |
52-Week High | $20.96 | $112.20 |
52-Week Low | $13.19 | $103.98 |
Typical Hold Time | 14 Days | 61 Days |
Enterprise Value | $1.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
TIP trades at $104.24 with minimal daily movement (+0.06%). Technical indicators show a bearish bias with moving averages signaling caution while oscillators remain neutral. The ETF faces headwinds from rising bond yields and inflationary pressures affecting fixed income markets. Recent institutional activity shows Envestnet Asset Management increased its stake by 3.5% in the latest quarter.
The outlook remains challenging amid persistent bond market volatility and rising interest rates. Investment opportunity exists for inflation-protected exposure, though risks include continued yield increases and geopolitical tensions driving oil prices higher. Current technical weakness suggests cautious positioning may be warranted until market conditions stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About iShares TIPS Bond ETF
TIP is the flagship ETF for U.S. Treasury Inflation-Protected Securities (TIPS). It tracks an index of government bonds whose principal value adjusts based on the Consumer Price Index (CPI), providing a direct hedge against rising inflation.
Read more on TIP →
